Cargando…

Methotrexate adversely affects immunogenicity to COVID-19 mRNA vaccines

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8178029/ http://dx.doi.org/10.1007/s40278-021-96729-4

Ejemplares similares

No adverse effects found for prenatal exposure to mRNA COVID-19 vaccine
Publicado: (2022)

Myocarditis rare after COVID-19 mRNA vaccination
Publicado: (2021)

Safety of mRNA COVID-19 vaccines during pregnancy
Publicado: (2022)

Immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients with primary brain tumors: a prospective cohort study
por: Massarweh, Amir, et al.
Publicado: (2022)

COVID-19 mRNA vaccines: acute allergic reaction and anaphylaxis
Publicado: (2021)

mRNA COVID-19 vaccines safe in patients with previous COVID-19 infections
Publicado: (2022)

Safety and immunogenicity of mRNA COVID‐19 vaccine in inpatients with muscular dystrophy
por: Saito, Tomoko, et al.
Publicado: (2022)

mRNA-based vs viral vector-based COVID-19 vaccines
Publicado: (2021)

Low rate of myocarditis/pericarditis after COVID-19 mRNA vaccines
Publicado: (2022)

Fourth-dose boosters with COVID-19 mRNA vaccines well tolerated
Publicado: (2022)

Cardiac risks higher after COVID-19 infection than mRNA vaccine
Publicado: (2022)

Impact of methotrexate on first-dose COVID-19 mRNA vaccination
por: Connolly, Caoilfhionn M, et al.
Publicado: (2021)

Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease
por: Haberman, Rebecca H, et al.
Publicado: (2021)

Younger males at greatest risk of myocarditis after mRNA-based COVID-19 vaccination
Publicado: (2022)

Safety profile of mRNA vaccines during first 6 months of the US COVID-19 vaccination programme reviewed
Publicado: (2022)

Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19
por: Lim, Wey Wen, et al.
Publicado: (2021)

Myocarditis following COVID-19 mRNA vaccination
por: Parmar, Kanak, et al.
Publicado: (2021)

586. Immunogenicity of COVID-19 mRNA Vaccines in Patients with Lymphoid Malignancies
por: Izaguirre, Natalie E, et al.
Publicado: (2021)

COVID-19 mRNA Vaccines Preserve Immunogenicity after Re-Freezing
por: Grau, Santiago, et al.
Publicado: (2022)

Immunogenicity, effectiveness, safety and psychological impact of COVID-19 mRNA vaccines
por: Alesci, Alessio, et al.
Publicado: (2022)

Adverse Events and Immunogenicity of mRNA-Based COVID-19 Vaccine among Healthcare Workers: A Single-Centre Experience
por: Sauserienė, Jolanta, et al.
Publicado: (2022)

Safety of mRNA-COVID-19 Vaccines in Patients With Thoracic Cancers
por: Spitaleri, G., et al.
Publicado: (2023)

Immunogenic amino acid motifs and linear epitopes of COVID-19 mRNA vaccines
por: Wisnewski, Adam V., et al.
Publicado: (2021)

Immunogenicity and Safety of COVID-19 mRNA Vaccine in STAT1 GOF Patients
por: Bloomfield, Marketa, et al.
Publicado: (2021)

Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis
por: Trougakos, Ioannis P., et al.
Publicado: (2022)

Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV
por: Vergori, Alessandra, et al.
Publicado: (2022)

Immunogenicity of COVID-19 Vaccination in Melanoma Patients under Immune Checkpoint Blockade
por: Niewolik, Jacqueline, et al.
Publicado: (2022)

Improving COVID-19 vaccine immunogenicity by interrupting methotrexate treatment
por: Sparks, Jeffrey A, et al.
Publicado: (2022)

Safety of COVID-19 mRNA vaccination in children with chronic urticaria
por: Zhu, Catherine K., et al.
Publicado: (2023)

Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan
por: Kitagawa, Hiroki, et al.
Publicado: (2022)

Immunogenicity of Sars-Cov-2 mRNA 1273 Vaccine in Patients with Lymphoid Malignancies
por: Dong, Ning, et al.
Publicado: (2021)

Allergic symptoms after mRNA COVID-19 vaccination and risk of incomplete vaccination
por: Robinson, Lacey B., et al.
Publicado: (2021)

Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models
por: Kalnin, Kirill V., et al.
Publicado: (2021)

Immunogenicity and safety of inactivated and mRNA COVID-19 vaccines in patients with systemic lupus erythematosus
por: So, Ho, et al.
Publicado: (2022)

Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity
por: van Leeuwen, Leanne P.M., et al.
Publicado: (2022)

Immunogenicity of COVID‐19 mRNA vaccines in hemodialysis patients: Systematic review and meta‐analysis
por: Falahi, Shahab, et al.
Publicado: (2022)

Immunogenicity of an mRNA-Based COVID-19 Vaccine among Adolescents with Obesity or Liver Transplants
por: Tubjaroen, Chomchanat, et al.
Publicado: (2022)

COVID-19 mRNA vaccine-induced adverse effects: unwinding the unknowns
por: Trougakos, Ioannis P., et al.
Publicado: (2022)

COVID-19 mRNA Vaccines: The Molecular Basis of Some Adverse Events
por: Giannotta, Girolamo, et al.
Publicado: (2023)

COVID-19 vaccine adverse events reported via app
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_m14356vu9pnt30tv0ck9jvnf33